Tags

Type your tag names separated by a space and hit enter

FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway.
Oncotarget. 2014 May 15; 5(9):2475-86.O

Abstract

The endocannabinoid anandamide (AEA), a neurotransmitter was shown to have anti-cancer effects. Fatty acid amide hydrolase (FAAH) metabolizes AEA and decreases its anti-tumorigenic activity. In this study, we have analyzed the role of FAAH inhibition in non-small cell lung cancer (NSCLC). We have shown that FAAH and CB1 receptor which is activated by AEA are expressed in lung adenocarcinoma patient samples and NSCLC cell lines A549 and H460. Since the synthetic analogue of anandamide (Met-F-AEA) did not possess significant anti-tumorigenic effects, we used Met-F-AEA in combination with FAAH inhibitor URB597 which significantly reduced EGF (epidermal growth factor)-induced proliferative and chemotactic activities in vitro when compared to anti-tumorigenic activity of Met-F-AEA alone. Further analysis of signaling mechanisms revealed that Met-F-AEA in combination with URB597 inhibits activation of EGFR and its downstream signaling ERK, AKT and NF-kB. In addition, it inhibited MMP2 secretion and stress fiber formation. We have also shown that the Met-F-AEA in combination with URB597 induces G0/G1 cell cycle arrest by downregulating cyclin D1 and CDK4 expressions, ultimately leading to apoptosis via activation of caspase-9 and PARP. Furthermore, the combination treatment inhibited tumor growth in a xenograft nude mouse model system. Tumors derived from Met-F-AEA and URB597 combination treated mice showed reduced EGFR, AKT and ERK activation and MMP2/MMP9 expressions when compared to Met-F-AEA or URB597 alone. Taken together, these data suggest in EGFR overexpressing NSCLC that the combination of Met-F-AEA with FAAH inhibitor resulted in superior therapeutic response compared to individual compound activity alone.

Authors+Show Affiliations

Department of Pathology, The Ohio State University, Ohio, USA.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Research Support, N.I.H., Extramural

Language

eng

PubMed ID

24811863

Citation

Ravi, Janani, et al. "FAAH Inhibition Enhances Anandamide Mediated Anti-tumorigenic Effects in Non-small Cell Lung Cancer By Downregulating the EGF/EGFR Pathway." Oncotarget, vol. 5, no. 9, 2014, pp. 2475-86.
Ravi J, Sneh A, Shilo K, et al. FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. Oncotarget. 2014;5(9):2475-86.
Ravi, J., Sneh, A., Shilo, K., Nasser, M. W., & Ganju, R. K. (2014). FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. Oncotarget, 5(9), 2475-86.
Ravi J, et al. FAAH Inhibition Enhances Anandamide Mediated Anti-tumorigenic Effects in Non-small Cell Lung Cancer By Downregulating the EGF/EGFR Pathway. Oncotarget. 2014 May 15;5(9):2475-86. PubMed PMID: 24811863.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - FAAH inhibition enhances anandamide mediated anti-tumorigenic effects in non-small cell lung cancer by downregulating the EGF/EGFR pathway. AU - Ravi,Janani, AU - Sneh,Amita, AU - Shilo,Konstantin, AU - Nasser,Mohd W, AU - Ganju,Ramesh K, PY - 2014/5/10/entrez PY - 2014/5/9/pubmed PY - 2015/2/20/medline SP - 2475 EP - 86 JF - Oncotarget JO - Oncotarget VL - 5 IS - 9 N2 - The endocannabinoid anandamide (AEA), a neurotransmitter was shown to have anti-cancer effects. Fatty acid amide hydrolase (FAAH) metabolizes AEA and decreases its anti-tumorigenic activity. In this study, we have analyzed the role of FAAH inhibition in non-small cell lung cancer (NSCLC). We have shown that FAAH and CB1 receptor which is activated by AEA are expressed in lung adenocarcinoma patient samples and NSCLC cell lines A549 and H460. Since the synthetic analogue of anandamide (Met-F-AEA) did not possess significant anti-tumorigenic effects, we used Met-F-AEA in combination with FAAH inhibitor URB597 which significantly reduced EGF (epidermal growth factor)-induced proliferative and chemotactic activities in vitro when compared to anti-tumorigenic activity of Met-F-AEA alone. Further analysis of signaling mechanisms revealed that Met-F-AEA in combination with URB597 inhibits activation of EGFR and its downstream signaling ERK, AKT and NF-kB. In addition, it inhibited MMP2 secretion and stress fiber formation. We have also shown that the Met-F-AEA in combination with URB597 induces G0/G1 cell cycle arrest by downregulating cyclin D1 and CDK4 expressions, ultimately leading to apoptosis via activation of caspase-9 and PARP. Furthermore, the combination treatment inhibited tumor growth in a xenograft nude mouse model system. Tumors derived from Met-F-AEA and URB597 combination treated mice showed reduced EGFR, AKT and ERK activation and MMP2/MMP9 expressions when compared to Met-F-AEA or URB597 alone. Taken together, these data suggest in EGFR overexpressing NSCLC that the combination of Met-F-AEA with FAAH inhibitor resulted in superior therapeutic response compared to individual compound activity alone. SN - 1949-2553 UR - https://www.unboundmedicine.com/medline/citation/24811863/FAAH_inhibition_enhances_anandamide_mediated_anti_tumorigenic_effects_in_non_small_cell_lung_cancer_by_downregulating_the_EGF/EGFR_pathway_ L2 - https://www.oncotarget.com/lookup/doi/10.18632/oncotarget.1723 DB - PRIME DP - Unbound Medicine ER -